Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer [Phase 2]
Phase II trial evaluating TQB3616 capsules for recurrent/metastatic breast cancer. The study status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers [Phase 1]
Phase Ib trial evaluating adagrasib (KRAS G12C inhibitor) in combination with olaparib in KRAS G12C-mutated advanced solid tumors, focusing …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement [Phase 4]
A Phase 4 clinical trial sponsored by Memorial Sloan Kettering Cancer Center is evaluating antibiotic delivery to prevent infection after br…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention [NA]
Clinical trial update describing the SHARE-MC educational intervention for sexual health and rehabilitation in women with metastatic breast …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer [Phase 1, Phase 2]
A Phase Ib/II clinical trial, ERADICATE, is evaluating elacestrant in combination with trastuzumab deruxtecan in patients with HR-positive, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Increasing Screening for Cancer Using EHR-Nudges Replication [NA]
This clinical trial update describes an active-not-recruiting replication study that investigates using electronic health record nudges to i…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE [NA]
Clinical trial update for a study aimed at improving patients' competence in persisting with oral endocrine therapy for breast cancer. Recru…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases [Phase 2]
Phase 2 trial evaluating cisplatin with or without veliparib in patients with recurrent or metastatic triple-negative or BRCA mutation-assoc…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer [Phase 3]
A Phase 3 trial evaluating BL-M07D1 in combination with pertuzumab versus standard therapy (docetaxel with trastuzumab and pertuzumab) for f…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer [Phase 2]
Phase 2 study evaluating TQB3616 capsules in combination with fulvestrant for advanced HR-positive, HER2-negative breast cancer has complete…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers [Phase 2]
Phase 2 clinical trial evaluating pre-operative Neratinib and Trastuzumab with endocrine therapy for ER-positive, HER2-positive breast cance…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail [Phase 3]
A Phase 3 trial evaluating TQB3616 capsules in combination with fulvestrant versus placebo with fulvestrant in previously treated HR-positiv…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Planning Grant for TOPS for Breast Cancer Survivors [NA]
Planning grant for the TOPS program to support weight management among breast cancer survivors; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating ribociclib in combination with endocrine therapy of physician's choice for locoregional recurrent, hormone…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. [Phase 3]
Phase 3 trial evaluating alpelisib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after prior CDK4/6 inhibitor and ar…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout® [NA]
A clinical trial update for a study comparing routine cavity shave margins versus selective margins in breast cancer using the Savi Scout de…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study [NA]
A completed clinical trial evaluating survivorship care plans and telehealth education (the IMPACT Study) aimed at improving access to cance…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer [Phase 3]
Clinical trial update for KN026 in combination with HB1801 as adjuvant therapy for resectable HER2-positive breast cancer, currently recruit…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer [Phase 2]
Phase 2 study assessing the efficacy and safety of combining alpelisib with fulvestrant in Japanese men and postmenopausal women with advanc…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer [NA]
This clinical trial examines whether an aerobic exercise program improves vascular function in women with non-metastatic breast cancer. The …
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer [NA]
Clinical trial update indicates ongoing recruitment for Signatera-guided CDK4/6 inhibitor therapy in breast cancer.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy [Phase 2]
Phase 2 study evaluating Coenzyme Q10 for neuroprotection against paclitaxel-induced neuropathy in breast cancer patients has completed. Spo…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Dance Study for Post-surgical Pain in Breast Cancer Survivors [NA]
This clinical trial update notes a study evaluating a dance-based intervention to address postoperative pain in breast cancer survivors. The…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Plant-Based Nutrition for Breast or Endometrial Cancer [NA]
A clinical trial investigating plant-based nutrition as an intervention for metastatic breast cancer and stage IV endometrial cancer is list…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer [Phase 3]
Phase 3 trial evaluating trastuzumab deruxtecan in hormone receptor-negative and hormone receptor-positive HER2-low or HER2 IHC 0 metastatic…